Cancer News and Research

Latest Cancer News and Research

BSD's MicroThermX Microwave Ablation System featured at CIRSE

BSD Medical Corporation announced today that the MicroThermX Microwave Ablation System was featured at the Company's exhibition booth at the international meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), which was held in Valencia, Spain, October 2-6, 2010.

15 Oct 2010

Scientists discover mechanism of anticancer drug to kill cancer cells

A potent drug derived from an evergreen tree may soon save the lives of some patients with the deadliest form of breast cancer. According to the National Cancer Institute, breast cancer will claim approximately 40,000 lives in the U.S. this year.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme Corporation today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.

15 Oct 2010

ACS awards Research Scholar Grant to Rensselaer researcher for breast cancer study

A recent Research Scholar Grant from the American Cancer Society acknowledges the potential of Rensselaer researcher Lee Ligon's work on breast cancer. Ligon is investigating interactions between cells as breast cancer spreads within the body.

15 Oct 2010

New, affordable technology for cervical cancer screening

Current cervical cancer screening is time consuming and expensive, but now new breakthrough technology developed by European researchers should allow large-range screening by non-medical personnel with almost immediate results and at a much lower cost.

15 Oct 2010

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.

15 Oct 2010

Scientists identify mechanism that regulate nuclear size

Size matters when it comes to the nucleus of a cell, and now scientists have discovered the signals that control how big the nucleus gets. Nuclear size varies not only among different species, but also in different types of cells in the same species and at different times during development. In addition, cancer cells are known to develop larger nuclei as they become more malignant. Screening for cervical cancer, for example, involves looking for grossly distorted nuclei in cervical cells collected during a Pap smear.

15 Oct 2010

FDG positron emission tomography allows early diagnosis of gall bladder cancer

Researchers at the University of Granada and the Department of Nuclear Medicine, Hospital Virgen de las Nieves at Granada found that the metabolic imaging diagnosis technique based on the analysis of a structural analog of glucose labeled with a positron-emitting compound (18F) allows early diagnosis of gall bladder cancer, a relatively rare disease with high mortality rates among most patients suffering from it.

15 Oct 2010

Moores Cancer Center files IND application for topical NexACT-based formulation

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).

15 Oct 2010

Robot-assisted brachytherapy for treating prostate cancer

In the first-of-a-kind clinical trial, a robot will be used to place therapeutic radioactive seeds in prostate cancer patients. The National Cancer Institute-supported study, which will enroll 14 patients, has just opened at Thomas Jefferson University Hospital.

15 Oct 2010

Cancer cluster among Sydney Harbour Bridge workers triggers investigation

There are reports of a cancer cluster among Sydney Harbour Bridge workers with at least eight known cases that unions believe are linked to the use of lead paint. The Roads and Traffic Authority (RTA) will investigate the matter. Of the eight workers five have already died and all of them had been involved in painting and maintaining the bridge for more than 10 years, the Construction Forestry Mining and Energy Union (CFMEU) said. This included scraping off lead paint, initially with little protective equipment.

14 Oct 2010

First national educational conference on Graft vs. Host Disease

The Case Comprehensive Cancer Center, together with the Meredith A. Cowden Foundation, will bring the first national educational conference on Graft vs. Host Disease (GvHD) to Cleveland on Thursday, Nov. 4, 8 a.m. to 6 p.m., at Corporate College East, 4400 Richmond Road, Warrenville Hts. GvHD is a life-threatening complication experienced by an estimated 60 percent of all leukemia and other blood cancer patients following bone marrow transplantation. There is currently no cure.

14 Oct 2010

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.

14 Oct 2010

Think Pink event offers information on breast care to lead healthier life

In recognition of Breast Cancer Awareness Month in October, Washington Women's Center is hosting "Think Pink Event: Breast Health - Navigating Uncertain Waters," which will take place on Thursday, October 14, from 5 to 7:30 p.m. under the tent atrium at Washington West, located at 2500 Mowry Ave. in Fremont, in the parking lot adjacent to Civic Center Road.

14 Oct 2010

Tiger Balm sponsors 15th annual Susan G. Komen Miami/Ft. Lauderdale Race for the Cure

Tiger Balm announced today its sponsorship of the 15th annual Susan G. Komen Miami/Ft. Lauderdale Race for the Cure®, taking place Saturday, October 16, 2010 in Miami's Bayfront Park.

14 Oct 2010

Scientists discover 'switch' mechanism of lymphatic and blood vessel cells

Scientists at the University of East Anglia have made an important breakthrough in the way anti-cancer drugs are tested. A tumour cannot grow to a large size or spread until it has developed its own blood supply and leading research has looked for a way of halting capillary formation to stop tumours taking hold.But new findings published today in the Journal of Cell Science have shown that scientists testing such treatments may not have been studying exactly what they thought they were.

14 Oct 2010

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

The Vision Center at Childrens Hospital Los Angeles has been awarded a $1 million grant from the National Cancer Institute (NCI) to conduct a clinical trial on a new drug delivery system to treat young children diagnosed with retinoblastoma. The device is designed to deliver chemotherapy through a tiny silicone cup sealed to the outer surface (sclera) of the eye, which can more directly target cancer cells and greatly reduce the side effects caused by current chemotherapy treatments.

14 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010

BNPD announces development of first commercial health drink product

BioCen Natural Products Development Group President Daniel J. Kennedy today commented, "We are pleased to announce that the development of BNPD's first commercial health drink, Vitamin "X" is near completion." For the past 8 weeks, BNPD has been performing test market analysis to determine the best flavor(s) and percentage of Astaxanthin actives for each bottle.

14 Oct 2010